125 results on '"Cahn, Avivit"'
Search Results
2. Reported iodinated contrast media allergy is a risk factor for anaphylaxis-independent mortality in hospitalized patients
3. Complex rearrangement in TBC1D4 in an individual with diabetes due to severe insulin resistance syndrome
4. Prescription patterns in people who are frail
5. Alpelisib in Intractable Non–Islet-Cell Tumor Hypoglycemia
6. Enterococci in diabetic foot infections: Prevalence, Clinical Characteristics, and Outcomes
7. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes
8. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
9. RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58
10. Glycemic Targets and Prevention of Chronic Complications
11. Glycemic Targets and Prevention of Chronic Complications
12. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58
13. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses from DECLARE-TIMI 58
14. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses from DECLARE-TIMI 58
15. SGLT2 Inhibitors and Safety in Older Patients
16. Acute diabetic foot in post kidney transplantation patients receiving chronic immunosuppression—clinical presentation and outcomes
17. Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes
18. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial
19. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
20. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial
21. Consistency of Thyroid Imaging Reporting and Data System Reporting in Community-Based Imaging Centers Versus a Large Tertiary Hospital
22. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
23. FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58
24. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
25. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
26. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
27. Predictors and outcomes of diabetic foot ulcer infection with ESBL-producing bacteria in a large tertiary center
28. Abstract 13182: Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis
29. Angiogenic potential of mesenchymal stem cells derived from patients with diabetes seeded on decellularized micro fragments
30. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
31. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
32. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
33. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial
34. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
35. Prevention of Diabetes in Israel
36. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
37. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
38. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
39. Machine learning based study of longitudinal HbA1c trends and their association with all‐cause mortality: Analyses from a National Diabetes Registry
40. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
41. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes
42. 788-P: The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbA1c: Analyses from DECLARE-TIMI 58
43. MEDIATION ANALYSIS FOR DAPAGLIFLOZIN AND THE REDUCTION IN HOSPITALIZATION FOR HEART FAILURE IN DECLARE-TIMI 58
44. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
45. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
46. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
47. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
48. Practical Approach to the Implementation of Diabetes Prevention
49. The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial
50. Abstract 14799: Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.